ReviewCurrent oncology reports2026
Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy of lenvatinib combined with sintilimab and transcatheter arterial chemoembolization in conversion therapy for unresectable hepatocellular carcinoma.Pakistan journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHepatocellular carcinoma (HCC) ranks among the most prevalent solid malignancies worldwide. A substantial proportion of patients are diagnosed at advanced stages, making systemic therapies the primary treatment option. In recent years, treatment strategies have shifted from single-agent targeted therapies, such as sorafenib and lenvatinib, to combination regimens incorporating immune checkpoint inhibitors, with or without antiangiogenic agents. This evolving treatment paradigm has led to an increasing number of patients receiving second-line and subsequent therapies. However, clinical guidelines for treatment selection remain lacking. RECENT
findingsCurrently, available salvage therapies include various molecularly targeted agents, immune checkpoint inhibitors, and combination regimens. Nonetheless, evidence supporting their efficacy and patient selection for specific strategies in this setting remains scarce. This review summarizes recent clinical advancements and explores emerging strategies to optimize systemic treatment options beyond first-line therapy in the increasingly complex landscape of advanced HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.